Prelude TherapeuticsPRLD
13F holders, Q3 2025 (September 30)At the end of Q3 2025, 47 institutions reported holding Prelude Therapeutics Inc. (PRLD) in their 13F filings, down 3 from Q2 2025. 5 opened new positions and 8 sold out. The largest holders were Orbimed Advisors LLC ($15.7M), Baker Bros. Advisors LP ($14.6M) and Millennium Management ($1.7M). 3 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Cliff Asness (0.0% of AQR Capital Management's portfolio).
- Company
- Prelude Therapeutics Inc.
- CUSIP
- 74065P101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $61K |
| Exits | 8 | $369K |
All 13F filers, Q2 2025 → Q3 2025: 1,038,799 shares bought and 1,064,751 shares sold, net −25,952 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 47 holders
| Orbimed Advisors LLC | 0.38% | No change | 10,909,256 | $15.7M |
| Baker Bros. Advisors LP | 0.11% | No change | 10,123,824 | $14.6M |
| Millennium Management | 0.00% | Add +361.7% | 1,147,044 | $1.7M |
| Vanguard Group Inc. | 0.00% | Add +6.5% | 992,854 | $1.4M |
| T. Rowe Price Associates Inc. | 0.00% | Reduce -5.5% | 876,338 | $1.3M |
| Renaissance Technologies | 0.00% | Reduce -6.5% | 544,000 | $783K |
| Acadian Asset Management LLC | 0.00% | No change | 540,565 | $777K |
| Morgan Stanley | 0.00% | Reduce -0.1% | 284,203 | $409K |
| BlackRock, Inc. | 0.00% | Reduce -38.7% | 264,973 | $382K |
| Two Sigma Advisers, LP | 0.00% | Reduce -1.0% | 222,700 | $321K |
| Geode Capital Management, LLC | 0.00% | No change | 217,568 | $313K |
| TD Asset Management Inc | 0.00% | No change | 160,652 | $231K |
| Two Sigma Investments, LP | 0.00% | Reduce -1.8% | 152,233 | $219K |
| Shay Capital LLC | 0.03% | Add +33.3% | 100,000 | $144K |
| State Street Corp. | 0.00% | No change | 97,592 | $141K |
| Goldman Sachs Group Inc. | 0.00% | Reduce -46.8% | 79,327 | $114K |
| Gsa Capital Partners LLP | 0.01% | Add +5.3% | 75,161 | $108K |
| Manufacturers Life Insurance Company, The | 0.00% | No change | 69,252 | $100K |
| Bridgeway Capital Management, LLC | 0.00% | Reduce -39.5% | 53,500 | $77K |
| Northern Trust Corp. | 0.00% | Reduce -4.5% | 36,421 | $52K |
| Jane Street Group, LLC | 0.00% | Reduce -62.0% | 34,822 | $50K |
| Cerity Partners LLC | 0.00% | Reduce -5.7% | 34,333 | $49K |
| Prudential Financial Inc. | 0.00% | New | 25,840 | $37K |
| HRT Financial LP | 0.00% | New | 16,901 | $24K |
| XTX Topco Ltd | 0.00% | Reduce -63.4% | 15,578 | $22K |
| HSBC Holdings PLC | 0.00% | Reduce -21.0% | 13,747 | $20K |
| AQR Capital Management | 0.00% | Reduce -75.9% | 10,500 | $15K |
| FMR LLC | 0.00% | Reduce -18.5% | 9,099 | $13K |
| Bank of America Corp. | 0.00% | Reduce -21.6% | 8,848 | $13K |
| Barclays PLC | 0.00% | Add +1.3% | 8,712 | $13K |
| Royal Bank of Canada | 0.00% | Add +172.8% | 7,712 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -58.8% | 6,927 | $10K |
| Citigroup Inc. | 0.00% | Add +26.6% | 5,975 | $9K |
| UBS Group AG | 0.00% | Reduce -96.0% | 4,171 | $6K |
| JPMorgan Chase & Co. | 0.00% | Add +99.0% | 3,879 | $6K |
| SBI Securities Co., Ltd. | 0.00% | No change | 2,741 | $4K |
| Nisa Investment Advisors, LLC | 0.00% | No change | 1,634 | $2K |
| Cwm, LLC | 0.00% | Reduce -69.6% | 1,219 | $2K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -0.8% | 1,171 | $2K |
| Group One Trading LLC | 0.00% | No change | 500 | $720 |
| EverSource Wealth Advisors, LLC | 0.00% | Reduce -39.9% | 89 | $128 |
| BNP Paribas Financial Markets | 0.00% | No change | 52 | $75 |
| Optiver Holding B.V. | 0.00% | New | 20 | $29 |
| IFP Advisors, Inc | 0.00% | Reduce -47.1% | 18 | $26 |
| Essential Partners LLC | 0.00% | Reduce -80.5% | 17 | $24 |
| Arax Advisory Partners | 0.00% | New | 15 | $22 |
| Simplex Trading, LLC | 0.00% | New | 153 | $0 |
"% of holder's portfolio" is PRLD's weight in each manager's 13F, not the share of Prelude Therapeutics Inc. the manager owns.